http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020503330-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D281-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D281-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
filingDate 2017-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2020-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2020503330-A
titleOfInvention Tianeptine oxalate and polymorphism
abstract Formula (I) (RS) -7- (3-chloro-6-methyl-6,11-dihydrodibenzo [c, f] [1,2] thiazepin-11-ylamino) heptanoic acid S, S-dioxide (Tianeptine) The oxalate / co-crystal of ()) is disclosed herein. In one aspect, the present disclosure also provides a formulation of tianeptine oxalate to be developed as a first generation therapy for the treatment of corticosteroid-induced psychological side effects.
priorityDate 2016-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010112051-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466807504

Total number of triples: 35.